循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究
|
摘要
目的:探究循环热灌注化疗联合替吉奥及热疗在老年胃癌癌性腹水中的临床治疗效果。方法:选取100例老年胃癌癌性腹水患者作为本次临床试验研究观察与分析对象,对照组50例患者给予循环热灌注化疗治疗,观察组50例患者给予循环热灌注化疗联合替吉奥及热疗治疗,对两组患者的临床治疗总有效率、不良反应发生率、生活质量等进行观察和对比。结果:观察组患者临床总有效率为66%,对照组患者临床总有效率为46%,差异具有统计学意义(P<0.05);观察组和对照组的不良反应发生率分别为20%和40%,差异具有统计学意义(P<0.05);观察组生活质量评分比对照组高,差异具有统计学意义(P<0.05)。结论 :对胃癌癌性腹水患者实施循环热灌注化疗联合替吉奥及热疗治疗,能够有效提高患者的临床疗效,改善患者的生活质量,不良反应可控,值得临床应用。
Objective:To explore and analyze the clinical therapeutic effect of combined cyclic thermoplastic chemotherapy with tiago and hyperthermia in the treatment of senile gastric cancer with cancerous ascites. Methods: 100 cases of elderly patients with gastric cancerous ascites as the observation and analysis of the clinical trials research object, the control group of 50 cases patients with circulating hot perfusion chemotherapy treatment, observation group of 50 cases patients with heat circulation perfusion chemotherapy combined for gonow and heat treatment, the clinical total effective rate of two groups of patients, the incidence of adverse reactions, such as the quality of life observation and comparison. Results:The total clinical efficiency was 66% in the observation group and 46% in the control group(P<0.05). The difference was statistically significant. The incidence of adverse reactions in the observation group and the control group was 20% and 40%(P<0.05), and the difference was statistically significant. The life quality score of the observation group was higher than that of the control group(P<0.05), and the difference was statistically significant. Conclusion:the combined therapy of cyclic thermoperfusion with tiago and hyperthermia can effectively improve the clinical efficacy and quality of life of patients with gastric cancer patients with ascites, and the controlled adverse reactions are worthy of clinical application.
Objective:To explore and analyze the clinical therapeutic effect of combined cyclic thermoplastic chemotherapy with tiago and hyperthermia in the treatment of senile gastric cancer with cancerous ascites. Methods: 100 cases of elderly patients with gastric cancerous ascites as the observation and analysis of the clinical trials research object, the control group of 50 cases patients with circulating hot perfusion chemotherapy treatment, observation group of 50 cases patients with heat circulation perfusion chemotherapy combined for gonow and heat treatment, the clinical total effective rate of two groups of patients, the incidence of adverse reactions, such as the quality of life observation and comparison. Results:The total clinical efficiency was 66% in the observation group and 46% in the control group(P<0.05). The difference was statistically significant. The incidence of adverse reactions in the observation group and the control group was 20% and 40%(P<0.05), and the difference was statistically significant. The life quality score of the observation group was higher than that of the control group(P<0.05), and the difference was statistically significant. Conclusion:the combined therapy of cyclic thermoperfusion with tiago and hyperthermia can effectively improve the clinical efficacy and quality of life of patients with gastric cancer patients with ascites, and the controlled adverse reactions are worthy of clinical application.
引文
[1] 毛丽伟,管静芝,廖国清.S-1联合DDP腹腔循环热灌注治疗老年胃癌合并腹水临床疗效观察[J].现代肿瘤医学,2014,22(12):2916-2918.
[2] 简朔.替吉奥联合顺铂腹腔恒温循环热灌注治疗对胃癌合并腹水患者恶性分子表达的影响及毒副反应评估[J].海南医学院学报,2016,22(15):1730-1732.
[3] 韩熙渊.替吉奥联合顺铂腹腔热灌注化疗治疗胃癌合并腹水17例临床观察[J].中国医药指南,2015,13(3):202-202.
[4] 陈宓.阿帕替尼联合热疗治疗晚期胃癌恶性腹水的临床研究[J].医药前沿,2016,6(36):123-125.
[5] 毛丽伟,王阳,廖国清.腹腔热灌注化疗对晚期胃癌患者外周血和腹水调节性T细胞的影响及意义[J].检验医学与临床,2016,13(17):2429-2431.
[6] 齐瑾,郑玉军,王明吉.洛铂腹腔灌注联合替吉奥治疗晚期胃癌合并腹水的临床观察[J].中国当代医药,2014,21(14):92-94.
[7] 李玉珠,李亚平.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的疗效及安全性[J].中国现代药物应用,2016,10(21):135-136.
[8] 邓正兴.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的效果及安全性分析[J].中国当代医药,2015,22(26):49-51.
[9] 柯于锋.替吉奥联合腹腔内化疗治疗胃癌合并腹腔积液的疗效观察[J].当代医学,2014,20(29):1238-1240.
[10] 王海存,曹旸,王兰荣.替吉奥联合顺铂腹腔恒温循环热灌注化疗对胃癌合并腹水患者恶性分子及免疫功能的影响[J].中国老年学,2016,36(23):5894-5896.
[11] 尚红娟,黄龙璋,邓泽锋.替吉奥联合腹腔化疗方案治疗胃癌腹水的临床效果观察[J].中国当代医药,2014,21(25):99-101.
[12] Do KT, Kastenmüller G, Mook-Kanamori DO.Network-based approach for analyzing intra- and interfluid metabolite associations in human blood, urine, and saliva[J].Journal of Proteome Research,2014,14(2):1183.
[13] Inman BA, Etienne W, Rubin R.The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment[J].Int J Hyperthermia,2013,29(3):206-210.
[14] Hasan MM, Nayem KA, Hossain MB.Production of Tissue Engineering Scaffolds from Poly Caprolactone (PCL) and Its Microscopic Analysis[J].International Journal of Textile Science,2014,3(3):39-43.
[15] Abiose SH, SH Ikujenlola SH, Aboderin FI.Nutritional quality assessment of complementary foods produced from fermented and malted Quality Protein Maize fortified with soy bean flour[J].Polish Journal of Food & Nutrition Sciences,2015,65(1):49-56.
[16] Hillyer M, Menon K, Singh R.The effects of dehydration on skill-based performance[J].International Journal of Sports Science,2015,5(3):99-107.
[17] Ammerlaan W,Trezzi JP,Mathay C.Method validation for preparing urine samples for downstream proteomic and metabolomic applications[J].Biopreservation & Biobanking,2014,12(5):351-357.
[18] 宾业鸿,郑海平,蓝东.SOX联合多西他赛腹腔灌注与DOS方案一线治疗晚期胃癌伴癌性腹水的对比研究[J].中华肿瘤防治杂志,2016,23(16):1085-1089.
[19] 类成海,颜慧.替吉奥联合奥沙利铂治疗老年晚期胃癌患者的临床疗效及安全性观察[J].中国实用医药,2017,12(5):137-138.
[20] 陈敏,李亚妮.热疗联合替吉奥单药治疗老年晚期胃癌的临床观察[J].中南医学科学杂志,2016,44(6):610-612.
[2] 简朔.替吉奥联合顺铂腹腔恒温循环热灌注治疗对胃癌合并腹水患者恶性分子表达的影响及毒副反应评估[J].海南医学院学报,2016,22(15):1730-1732.
[3] 韩熙渊.替吉奥联合顺铂腹腔热灌注化疗治疗胃癌合并腹水17例临床观察[J].中国医药指南,2015,13(3):202-202.
[4] 陈宓.阿帕替尼联合热疗治疗晚期胃癌恶性腹水的临床研究[J].医药前沿,2016,6(36):123-125.
[5] 毛丽伟,王阳,廖国清.腹腔热灌注化疗对晚期胃癌患者外周血和腹水调节性T细胞的影响及意义[J].检验医学与临床,2016,13(17):2429-2431.
[6] 齐瑾,郑玉军,王明吉.洛铂腹腔灌注联合替吉奥治疗晚期胃癌合并腹水的临床观察[J].中国当代医药,2014,21(14):92-94.
[7] 李玉珠,李亚平.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的疗效及安全性[J].中国现代药物应用,2016,10(21):135-136.
[8] 邓正兴.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的效果及安全性分析[J].中国当代医药,2015,22(26):49-51.
[9] 柯于锋.替吉奥联合腹腔内化疗治疗胃癌合并腹腔积液的疗效观察[J].当代医学,2014,20(29):1238-1240.
[10] 王海存,曹旸,王兰荣.替吉奥联合顺铂腹腔恒温循环热灌注化疗对胃癌合并腹水患者恶性分子及免疫功能的影响[J].中国老年学,2016,36(23):5894-5896.
[11] 尚红娟,黄龙璋,邓泽锋.替吉奥联合腹腔化疗方案治疗胃癌腹水的临床效果观察[J].中国当代医药,2014,21(25):99-101.
[12] Do KT, Kastenmüller G, Mook-Kanamori DO.Network-based approach for analyzing intra- and interfluid metabolite associations in human blood, urine, and saliva[J].Journal of Proteome Research,2014,14(2):1183.
[13] Inman BA, Etienne W, Rubin R.The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment[J].Int J Hyperthermia,2013,29(3):206-210.
[14] Hasan MM, Nayem KA, Hossain MB.Production of Tissue Engineering Scaffolds from Poly Caprolactone (PCL) and Its Microscopic Analysis[J].International Journal of Textile Science,2014,3(3):39-43.
[15] Abiose SH, SH Ikujenlola SH, Aboderin FI.Nutritional quality assessment of complementary foods produced from fermented and malted Quality Protein Maize fortified with soy bean flour[J].Polish Journal of Food & Nutrition Sciences,2015,65(1):49-56.
[16] Hillyer M, Menon K, Singh R.The effects of dehydration on skill-based performance[J].International Journal of Sports Science,2015,5(3):99-107.
[17] Ammerlaan W,Trezzi JP,Mathay C.Method validation for preparing urine samples for downstream proteomic and metabolomic applications[J].Biopreservation & Biobanking,2014,12(5):351-357.
[18] 宾业鸿,郑海平,蓝东.SOX联合多西他赛腹腔灌注与DOS方案一线治疗晚期胃癌伴癌性腹水的对比研究[J].中华肿瘤防治杂志,2016,23(16):1085-1089.
[19] 类成海,颜慧.替吉奥联合奥沙利铂治疗老年晚期胃癌患者的临床疗效及安全性观察[J].中国实用医药,2017,12(5):137-138.
[20] 陈敏,李亚妮.热疗联合替吉奥单药治疗老年晚期胃癌的临床观察[J].中南医学科学杂志,2016,44(6):610-612.